Uridine-based gadolinium complex and MRI contrast agent including the same
US9290535B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 15, 2012 |
| Grant date | Mar 22, 2016 |
| Priority date | — |
| Expiry date | Apr 15, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/067
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a new uridine nucleoside-based amphiphilic gadolinium complex and a magnetic resonance imaging (MRI) contrast agent including the gadolinium complex. The MRI contrast agent has high relaxivity, high binding affinity for and stability in human serum albumin, pH response, and high liver specificity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.